Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

NCT00773838 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: Vorinostat
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC